[{"data":1,"prerenderedAt":280},["ShallowReactive",2],{"$f36gkhje121nlx":3},{"schema":4,"slug":5,"series":6,"series_slug":7,"name":8,"year":9,"therapeutic_area":10,"generated_at":11,"counts":12,"top_targets":23,"top_modalities":59,"top_diseases":84,"top_companies":117,"key_results":147,"trends":231,"previous_editions":240,"comparison":244,"highlighted_classes":274},1,"eha-2026","EHA","eha","EHA Congress 2026",2026,"Hematology","2026-11-05T22:19:09Z",{"abstracts":13,"drug_linked":14,"companies":15,"by_phase":16},2981,1687,265,{"Phase 1":17,"Phase 1\u002F2":18,"Phase 2":19,"Phase 4":20,"Phase 2\u002F3":21,"Phase 3":22},89,69,184,3,9,144,[24,28,32,35,38,42,45,49,53,56],{"name":25,"count":26,"share":27},"BCL-2",161,10,{"name":29,"count":30,"share":31},"BTK",126,7,{"name":33,"count":34,"share":31},"CD3",121,{"name":36,"count":37,"share":31},"CD19",116,{"name":39,"count":40,"share":41},"ABL1",103,6,{"name":43,"count":44,"share":41},"CD20",96,{"name":46,"count":47,"share":48},"BCMA",83,5,{"name":50,"count":51,"share":52},"KIT",72,4,{"name":54,"count":55,"share":20},"TOP2A",44,{"name":57,"count":58,"share":20},"DNMT1",43,[60,64,68,70,73,76,78,81],{"name":61,"count":62,"share":63},"Small molecules",1038,62,{"name":65,"count":66,"share":67},"Monoclonal antibodies",189,11,{"name":69,"count":19,"share":67},"Cell therapies",{"name":71,"count":72,"share":31},"Bispecific antibodies",120,{"name":74,"count":75,"share":52},"Non-antibody therapeutic proteins",75,{"name":77,"count":63,"share":52},"Antibody-drug conjugates",{"name":79,"count":80,"share":4},"Blood, tissue and cell-derived products",25,{"name":82,"count":83,"share":4},"Peptides",21,[85,89,93,96,98,101,104,107,110,113],{"name":86,"count":87,"share":88},"acute myeloid leukemia (AML)",370,22,{"name":90,"count":91,"share":92},"multiple myeloma (MM)",195,12,{"name":94,"count":95,"share":21},"acute lymphoblastic leukemia (ALL)",154,{"name":97,"count":95,"share":21},"diffuse large B-cell lymphoma (DLBCL)",{"name":99,"count":100,"share":21},"chronic lymphocytic leukemia\u002Fsmall lymphocytic lymphoma (CLL\u002FSLL)",146,{"name":102,"count":103,"share":41},"myelodysplastic syndrome (MDS)",100,{"name":105,"count":106,"share":41},"chronic myelogenous leukemia (CML)",93,{"name":108,"count":109,"share":20},"follicular lymphoma (FL)",53,{"name":111,"count":112,"share":20},"paroxysmal nocturnal hemoglobinuria (PNH)",50,{"name":114,"count":115,"share":116},"myelofibrosis (MF)",40,2,[118,121,124,127,130,133,135,138,141,144],{"name":119,"count":120,"share":27},"AbbVie",169,{"name":122,"count":123,"share":31},"Novartis",111,{"name":125,"count":126,"share":41},"Bristol Myers Squibb",106,{"name":128,"count":129,"share":52},"Pfizer",66,{"name":131,"count":132,"share":20},"Genentech",51,{"name":134,"count":112,"share":20},"Johnson & Johnson",{"name":136,"count":137,"share":20},"Amgen",48,{"name":139,"count":140,"share":116},"GSK",41,{"name":142,"count":143,"share":116},"Pharmacyclics",38,{"name":145,"count":146,"share":116},"BeiGene",37,[148,156,163,169,176,184,190,197,203,210,216,224],{"title":149,"drug":150,"company":152,"phase":153,"disease":90,"finding":154,"url":155},"MAJESTEC-9: a phase 3 study of teclistamab monotherapy vs pomalidomide\u002Fbortezomib\u002Fdexamethasone or carfilzomib\u002Fdexamethasone (PVd\u002FKd) in patients (pts) with relapsed refractory multiple myeloma (RRMM)",{"name":151,"slug":151},"teclistamab",null,"Phase 3","With 17.3-mo median follow-up, Tec significantly improved PFS vs PVd\u002FKd (HR, 0.29; 95% CI, 0.23–0.38; P\u003C0.0001); mPFS: NR vs 8.2 mo; 18-mo PFS rate: 69.8% vs 26.9%.","https:\u002F\u002Flibrary.ehaweb.org\u002Feha\u002F2026\u002Feha-2026\u002F4206749\u002Fcyrille.touzeau.majestec-9.a.phase.3.study.of.teclistamab.monotherapy.vs.html?f=ce_id%3D2934",{"title":157,"drug":158,"company":152,"phase":153,"disease":160,"finding":161,"url":162},"Phase 3 randomized trial of anselamimab demonstrates improvement in All-cause mortality in κ light-chain amyloidosis",{"name":159,"slug":159},"anselamimab","light-chain amyloidosis","Anselamimab-treated patients with κ iFLC had a 62% reduction in ACM (HR = 0.38; 95% CI, 0.17, 0.86; nominal P = 0.012) and a 71% reduction in risk for CVH (estimated CVH rate ratio = 0.29; 95% CI, 0.10, 0.87; nominal P = 0.028).","https:\u002F\u002Flibrary.ehaweb.org\u002Feha\u002F2026\u002Feha-2026\u002F4206760\u002Fashutosh.wechalekar.phase.3.randomized.trial.of.anselamimab.demonstrates.html?f=ce_id%3D2934",{"title":164,"drug":165,"company":152,"phase":153,"disease":97,"finding":167,"url":168},"Results from EPCORE DLBCL-1: randomized phase 3 study of epcoritamab (epcor) vs investigator’s choice chemoimmunotherapy (CIT) in patients with relapsed\u002Frefractory large b-cell lymphoma (R\u002FR LBCL)",{"name":166,"slug":166},"epcoritamab","A statistically significant improvement in PFS was demonstrated with epcor vs CIT (HR, 0.74 [95% CI, 0.60–0.92]; P=0.0059; 24-mo PFS: 30% vs 13%).","https:\u002F\u002Flibrary.ehaweb.org\u002Feha\u002F2026\u002Feha-2026\u002F4206789\u002Fchristopher.p.fox.results.from.epcore.dlbcl-1.randomized.phase.3.study.of.html?f=ce_id%3D2934",{"title":170,"drug":171,"company":152,"phase":153,"disease":111,"finding":174,"url":175},"Oral MY008211A demonstrates superior efficacy versus eculizumab in complement inhibitor–naïve Chinese patients with paroxysmal nocturnal hemoglobinuria (PNH)",{"name":172,"slug":173},"MY-008","my-008","A significantly greater proportion of patients in the MY008211A arm achieved the primary endpoint compared with the eculizumab arm (50.0% versus 9.1%; odds ratio, 19.0; 95% CI, 3.62–99.67; P=0.0005 for superiority).","https:\u002F\u002Flibrary.ehaweb.org\u002Feha\u002F2026\u002Feha-2026\u002F4208339\u002Ffengkui.zhang.oral.my008211a.demonstrates.superior.efficacy.versus.eculizumab.html?f=ce_id%3D2934",{"title":177,"drug":178,"company":152,"phase":153,"disease":181,"finding":182,"url":183},"Randomized phase 3 trial of watchful waiting versus interferon-alfa and zidovudine for indolent adult T-cell leukemia-lymphoma: JCOG1111C",{"name":179,"slug":180},"interferon alfa","interferon-alfa","adult T-cell leukemia-lymphoma (ATLL)","Median overall survival (OS) was NE in both arms (HR: 0.94, 95% CI: 0.33–2.67).","https:\u002F\u002Flibrary.ehaweb.org\u002Feha\u002F2026\u002Feha-2026\u002F4208695\u002Fkenji.ishitsuka.randomized.phase.3.trial.of.watchful.waiting.versus.html?f=ce_id%3D2934",{"title":185,"drug":186,"company":152,"phase":153,"disease":97,"finding":188,"url":189},"R-GemOx+nivolumab vs R-GemOx as 2ND-LINE therapy for large B-cell lymphoma in transplant-ineligible patients: final analysis of the NIVEAU trial, a phase 3 study of the agmt, gla, hovon, lysa and plrg",{"name":187,"slug":187},"nivolumab","At 2 years, PFS, EFS and OS were 19% (12-26), 17% (10-23) and 39% (30-47) vs. 18% (11-24), 17% (10-23) and 42% (33-50).","https:\u002F\u002Flibrary.ehaweb.org\u002Feha\u002F2026\u002Feha-2026\u002F4207981\u002Fgerhard.held.r-gemox2Bnivolumab.vs.r-gemox.as.2nd-line.therapy.for.large.b-cell.html?f=ce_id%3D2934",{"title":191,"drug":192,"company":152,"phase":153,"disease":97,"finding":195,"url":196},"Polatuzumab vedotin plus rituximab, ifosfamide, carboplatin, etoposide (Pola-R-ICE) vs R-ICE as second line treatment in large b cell lymphoma (LBCL). final analysis of a randomized phase 3 study",{"name":193,"slug":194},"polatuzumab vedotin","polatuzumab-vedotin","With a median observation time of 24.6 months, there was no statistically significant difference between Pola-R-ICE and R-ICE at 2 years in EFS (26% vs 30%), PFS (47% vs 41%) and OS (75% vs 64%).","https:\u002F\u002Flibrary.ehaweb.org\u002Feha\u002F2026\u002Feha-2026\u002F4206791\u002Fbertram.glass.polatuzumab.vedotin.plus.rituximab.ifosfamide.carboplatin.html?f=ce_id%3D2934",{"title":198,"drug":199,"company":152,"phase":153,"disease":97,"finding":201,"url":202},"Mosunetuzumab plus polatuzumab vedotin versus rituximab, gemcitabine and oxaliplatin in large B-cell lymphoma: updated efficacy and safety from the phase 3 SUNMO study including in patient subgroups",{"name":200,"slug":200},"mosunetuzumab","The observed PFS benefit of Mosun-Pola over R-GemOx was similar in 2L (HR, 0.38; 95% CI: 0.22–0.67) and 3L+ (HR, 0.48; 95% CI: 0.29–0.81) subgroups.","https:\u002F\u002Flibrary.ehaweb.org\u002Feha\u002F2026\u002Feha-2026\u002F4207956\u002Fl.elizabeth.budde.mosunetuzumab.plus.polatuzumab.vedotin.versus.rituximab.html?f=ce_id%3D2934",{"title":204,"drug":205,"company":152,"phase":153,"disease":207,"finding":208,"url":209},"Eltrombopag plus cyclosporine a for moderate aplastic anemia (EMAA), a placebo-controlled, double-blind, randomized phase 3 trial: treatment modifications after double blind treatment period",{"name":206,"slug":206},"eltrombopag","aplastic anemia","First line EPAG treatment significantly improved trilineage ORR after 12 wks (48.8% [95 % CI, 34.3; 63.5] vs. 25% ([95 % CI, 14.4; 39.6] p=0.02) and 24 wks (71.4% [95 % CI, 54.8; 83.8],in 35\u002F41 pts) vs. 42.5% [95 % CI, 28.5; 57.8]; in 40\u002F44pts; p = 0.011).","https:\u002F\u002Flibrary.ehaweb.org\u002Feha\u002F2026\u002Feha-2026\u002F4206738\u002Fbritta.hchsmann.eltrombopag.plus.cyclosporine.a.for.moderate.aplastic.anemia.html?f=ce_id%3D2934",{"title":211,"drug":212,"company":152,"phase":153,"disease":90,"finding":214,"url":215},"Daratumumab plus bortezomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: final analysis of transplant-ineligible patients in the phase 3 CEPHEUS study",{"name":213,"slug":213},"daratumumab","Median investigator-assessed PFS was not estimable (NE; 95% CI 74.81–NE) for DVRd and was 50.20 mo (95% CI 41.95–62.95) for VRd (hazard ratio [HR] 0.55; 95% CI 0.39–0.78; P=0.0007), with 59.3% for DVRd vs 38.3% for VRd alive and progression free at 72 mo.","https:\u002F\u002Flibrary.ehaweb.org\u002Feha\u002F2026\u002Feha-2026\u002F4206750\u002Fsaad.z.usmani.daratumumab.plus.bortezomib.lenalidomide.and.dexamethasone.in.html?f=ce_id%3D2934",{"title":217,"drug":218,"company":152,"phase":153,"disease":221,"finding":222,"url":223},"Early versus Delayed initiation of ropeginterferon ALFA-2B in high-risk essential thrombocythaemia: two-year results from the phase 3 SURPASS-ET study",{"name":219,"slug":220},"ropeginterferon alfa-2b","ropeginterferon-alfa-2b","thrombocythemia","At 24 months, estimated PFS was 76.9% (95% CI 66.4%–84.4%) in the Early P1101 group versus 43.1% (95% CI 30.6%–55.0%) in the Delayed P1101 group.","https:\u002F\u002Flibrary.ehaweb.org\u002Feha\u002F2026\u002Feha-2026\u002F4206773\u002Fharinder.gill.early.versus.delayed.initiation.of.ropeginterferon.alfa-2b.in.html?f=ce_id%3D2934",{"title":225,"drug":226,"company":139,"phase":153,"disease":90,"finding":229,"url":230},"Belantamab mafodotin, bortezomib, and dexamethasone vs daratumumab, bortezomib, and dexamethasone in relapsed\u002Frefractory multiple myeloma: updated 4-YEAR results of the phase 3 DREAMM-7 trial",{"name":227,"slug":228},"belantamab mafodotin","belantamab-mafodotin","In the intention-to-treat (ITT) population, median OS in the BVd arm was not reached (NR; 95% CI, 63.0 months-NR) and was 58.3 months (95% CI, 41.4 months-NR) in the DVd arm (HR, 0.62; 95% CI, 0.46-0.82).","https:\u002F\u002Flibrary.ehaweb.org\u002Feha\u002F2026\u002Feha-2026\u002F4208413\u002Fvania.hungria.belantamab.mafodotin.bortezomib.and.dexamethasone.vs.daratumumab.html?f=ce_id%3D2934",{"summary":232,"bullets":234},[233],"Monoclonal antibodies accounted for 11% of drug-linked abstracts, down from 14% in 2025. Small molecules, the most frequent modality, accounted for 62% of drug-linked abstracts, up from 59% in 2025. KIT (4%), DNMT1 (3%) and TOP2A (3%) were new to the top targets compared with 2025.",[235,236,237,238,239],"BCL-2 was the most frequent target (10% of drug-linked abstracts).","Acute myeloid leukemia (AML) was the most frequent disease (22%).","AbbVie had the largest company share (10%).","ABL1 accounted for 6% of drug-linked abstracts, up from 4% in 2025.","BCL-2 accounted for 10% of drug-linked abstracts, up from 8% in 2025.",[241],{"year":242,"abstracts":243},2025,3614,{"previous_year":242,"abstracts":245,"targets":248,"modalities":261,"new_in_top_targets":272,"new_in_top_modalities":273},{"previous":243,"current":13,"change_pct":246,"direction":247},18,"fell",[249,252,255,258],{"name":39,"count":40,"share":41,"previous_count":250,"previous_share":52,"direction":251},71,"rose",{"name":25,"count":26,"share":27,"previous_count":253,"previous_share":254,"direction":251},151,8,{"name":256,"count":257,"share":116,"previous_count":18,"previous_share":52,"direction":247},"CD38",36,{"name":259,"count":260,"share":116,"previous_count":18,"previous_share":52,"direction":247},"TUBB",42,[262,265,267,270],{"name":61,"count":62,"share":63,"previous_count":263,"previous_share":264,"direction":251},1091,59,{"name":69,"count":19,"share":67,"previous_count":266,"previous_share":21,"direction":251},162,{"name":65,"count":66,"share":67,"previous_count":268,"previous_share":269,"direction":247},259,14,{"name":74,"count":75,"share":52,"previous_count":271,"previous_share":41,"direction":247},115,[57,50,54],[],[275,278],{"name":77,"count":63,"share":52,"previous_count":276,"previous_share":48,"direction":277},94,"flat",{"name":71,"count":72,"share":31,"previous_count":279,"previous_share":31,"direction":277},127,1793970603082]